US20050119470A1
(en)
*
|
1996-06-06 |
2005-06-02 |
Muthiah Manoharan |
Conjugated oligomeric compounds and their use in gene modulation
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20040203024A1
(en)
*
|
1996-06-06 |
2004-10-14 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
US20040171031A1
(en)
*
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US20050042647A1
(en)
*
|
1996-06-06 |
2005-02-24 |
Baker Brenda F. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
US7812149B2
(en)
*
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US20040147022A1
(en)
*
|
1996-06-06 |
2004-07-29 |
Baker Brenda F. |
2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
US20050053976A1
(en)
*
|
1996-06-06 |
2005-03-10 |
Baker Brenda F. |
Chimeric oligomeric compounds and their use in gene modulation
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
WO2000044914A1
(en)
|
1999-01-28 |
2000-08-03 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
US7601494B2
(en)
|
1999-03-17 |
2009-10-13 |
The University Of North Carolina At Chapel Hill |
Method of screening candidate compounds for susceptibility to biliary excretion
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
WO2003070918A2
(en)
|
2002-02-20 |
2003-08-28 |
Ribozyme Pharmaceuticals, Incorporated |
Rna interference by modified short interfering nucleic acid
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
JP2003526367A
(ja)
*
|
2000-03-16 |
2003-09-09 |
ジェネティカ インコーポレイテッド |
Rna干渉の方法とrna干渉組成物
|
US8202846B2
(en)
*
|
2000-03-16 |
2012-06-19 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
PT1309726E
(pt)
|
2000-03-30 |
2010-03-08 |
Whitehead Biomedical Inst |
Mediadores de interferência por rna específicos de sequência de rna
|
DK2813582T3
(en)
|
2000-12-01 |
2017-07-31 |
Max-Planck-Gesellschaft Zur Förderung Der Wss E V |
Small RNA molecules that mediate RNA interference
|
WO2003035869A1
(de)
*
|
2001-10-26 |
2003-05-01 |
Ribopharma Ag |
Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
|
US7423142B2
(en)
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
EP2264173A3
(de)
|
2001-01-09 |
2015-01-14 |
Alnylam Europe AG |
Verwendung einer doppelsträngigen Ribonukleinsäure zur gezielten Hemmung der Expression eines vorgegebenen Zielgens
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
US20050148530A1
(en)
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050196765A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
US20040019001A1
(en)
*
|
2002-02-20 |
2004-01-29 |
Mcswiggen James A. |
RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
|
US20050203040A1
(en)
*
|
2001-05-18 |
2005-09-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
US20050288242A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
|
US20050124566A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US20050159381A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)
|
US20050196767A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
|
US20050159382A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US20050143333A1
(en)
*
|
2001-05-18 |
2005-06-30 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050182007A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050233997A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US20050158735A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
|
US20050176025A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
|
CA2453183C
(en)
|
2001-07-12 |
2016-05-10 |
University Of Massachusetts |
In vivo production of small interfering rnas that mediate gene silencing
|
US10590418B2
(en)
|
2001-07-23 |
2020-03-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for RNAi mediated inhibition of gene expression in mammals
|
US20030153519A1
(en)
|
2001-07-23 |
2003-08-14 |
Kay Mark A. |
Methods and compositions for RNAi mediated inhibition of gene expression in mammals
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
DE10163098B4
(de)
|
2001-10-12 |
2005-06-02 |
Alnylam Europe Ag |
Verfahren zur Hemmung der Replikation von Viren
|
FR2832154B1
(fr)
|
2001-11-09 |
2007-03-16 |
Centre Nat Rech Scient |
Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
|
JP4242590B2
(ja)
*
|
2002-01-11 |
2009-03-25 |
俊一 塩澤 |
慢性関節リウマチの疾患感受性遺伝子、及びその利用
|
DE10202419A1
(de)
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
|
EP2213737B1
(de)
|
2002-02-01 |
2012-11-07 |
Life Technologies Corporation |
Doppelsträngige Oligonukleotide
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
AU2003207708A1
(en)
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
JP2005517452A
(ja)
*
|
2002-02-20 |
2005-06-16 |
サーナ・セラピューティクス・インコーポレイテッド |
短干渉核酸(siNA)を用いるBCL2遺伝子発現のRNA干渉媒介性阻害
|
WO2004016735A2
(en)
|
2002-05-23 |
2004-02-26 |
Ceptyr, Inc. |
Modulation of biological signal transduction by rna interference
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
WO2004013288A2
(en)
|
2002-08-01 |
2004-02-12 |
City Of Hope |
Methods and kits for synthesis of sirna expression cassettes
|
US20050042646A1
(en)
|
2002-08-05 |
2005-02-24 |
Davidson Beverly L. |
RNA interference suppresion of neurodegenerative diseases and methods of use thereof
|
US20040241854A1
(en)
|
2002-08-05 |
2004-12-02 |
Davidson Beverly L. |
siRNA-mediated gene silencing
|
US20080274989A1
(en)
|
2002-08-05 |
2008-11-06 |
University Of Iowa Research Foundation |
Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
|
AU2003261449A1
(en)
|
2002-08-07 |
2004-02-25 |
|
Compositions for rna interference and methods of use thereof
|
US7892793B2
(en)
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
WO2004044132A2
(en)
*
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
JP4526228B2
(ja)
*
|
2002-11-22 |
2010-08-18 |
隆 森田 |
RNAiによる新規治療法および治療剤
|
US20040248299A1
(en)
*
|
2002-12-27 |
2004-12-09 |
Sumedha Jayasena |
RNA interference
|
GB0306148D0
(en)
*
|
2003-03-18 |
2003-04-23 |
Milner Jo |
Regulation of gene expression
|
CA2520181A1
(en)
*
|
2003-03-26 |
2004-10-14 |
Astral Inc. |
Selected rna motifs to include cell death and/or apoptosis
|
EP2251039A3
(de)
|
2003-05-30 |
2010-12-08 |
Nippon Shinyaku Co., Ltd. |
Doppelsträngige Oligo-RNA zum Hemmen der Expression von BCL-2 und sie enthaltende pharmazeutische Zusammensetzung
|
KR20060063788A
(ko)
*
|
2003-05-30 |
2006-06-12 |
니뽄 신야쿠 가부시키가이샤 |
올리고 핵산 담지 복합체, 이 복합체를 함유하는 의약조성물
|
ES2864206T3
(es)
|
2003-06-02 |
2021-10-13 |
Univ Massachusetts |
Métodos y composiciones para mejorar la eficacia y la especificidad del ARNi
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
ES2712695T3
(es)
|
2003-06-02 |
2019-05-14 |
Univ Massachusetts |
Métodos y composiciones para controlar la eficacia de la silenciación del ARN
|
EP3604537B1
(de)
*
|
2003-06-13 |
2021-12-08 |
Alnylam Europe AG |
Doppelsträngige ribonukleinsäure mit erhöhter wirksamkeit in einem organismus
|
EP1486564A1
(de)
*
|
2003-06-13 |
2004-12-15 |
Ribopharma AG |
SiRNA mit erhöhter Stabilität in Serum
|
EP1636342A4
(de)
*
|
2003-06-20 |
2008-10-08 |
Isis Pharmaceuticals Inc |
Oligomere verbindungen zur verwendung bei der modulation von genen
|
ITRM20030335A1
(it)
*
|
2003-07-09 |
2005-01-10 |
Univ Roma |
Sistema di espressione di sirna.
|
US8680063B2
(en)
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
ES2485848T3
(es)
|
2003-09-12 |
2014-08-14 |
University Of Massachusetts |
ARN de interferencia para el tratamiento de trastornos relacionados con la ganancia de función
|
US20060134787A1
(en)
|
2004-12-22 |
2006-06-22 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
|
EP1713915B1
(de)
|
2004-02-10 |
2009-12-16 |
Sirna Therapeutics, Inc. |
RNA-INTERFERENZ-VERMITTELTE HEMMUNG DER GENEXPRESSION UNTER VERWENDUNG MULTIFUNKTIONELLER siNA (SHORT INTERFERING NUCLEIC ACID)
|
US20060019914A1
(en)
|
2004-02-11 |
2006-01-26 |
University Of Tennessee Research Foundation |
Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
|
US8569474B2
(en)
*
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
EP1735009A4
(de)
|
2004-03-12 |
2011-03-30 |
Alnylam Pharmaceuticals Inc |
Irna mittel targeting vegf
|
EP1747022A4
(de)
|
2004-04-23 |
2010-03-31 |
Univ Columbia |
Hemmung von haarloser protein mrna
|
EP1740191A4
(de)
|
2004-04-28 |
2008-07-30 |
Univ Brigham Young |
Verwendung von equol zur behandlung von hauterkrankungen
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
CA2572450A1
(en)
*
|
2004-05-28 |
2005-12-15 |
Ambion, Inc. |
Methods and compositions involving microrna
|
US8394947B2
(en)
*
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
AU2005252663B2
(en)
*
|
2004-06-03 |
2011-07-07 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
CA2579574A1
(en)
|
2004-07-23 |
2007-01-04 |
The University Of North Carolina At Chapel Hill |
Methods and materials for determining pain sensitivity and predicting and treating related disorders
|
US20060040391A1
(en)
*
|
2004-08-20 |
2006-02-23 |
Promega Corporation |
RNA interference vectors
|
WO2006022325A1
(ja)
|
2004-08-26 |
2006-03-02 |
Nippon Shinyaku Co., Ltd. |
ガラクトース誘導体、薬物担体及び医薬組成物
|
US7884086B2
(en)
*
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
WO2006035432A2
(en)
*
|
2004-09-27 |
2006-04-06 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Gene silencing for use in dermatology
|
DK2302055T3
(da)
|
2004-11-12 |
2014-10-13 |
Asuragen Inc |
Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler
|
WO2007011702A2
(en)
|
2005-07-15 |
2007-01-25 |
The University Of North Carolina At Chapel Hill |
Use of egfr inhibitors to prevent or treat obesity
|
US20070161591A1
(en)
|
2005-08-18 |
2007-07-12 |
University Of Massachusetts |
Methods and compositions for treating neurological disease
|
WO2007039454A1
(en)
|
2005-09-20 |
2007-04-12 |
Basf Plant Science Gmbh |
Methods for controlling gene expression using ta-siran
|
US8093369B2
(en)
|
2005-10-11 |
2012-01-10 |
Ben Gurion University Of The Negev Research And Development Authority Ltd. |
Compositions for silencing the expression of VDAC1 and uses thereof
|
EP2325315B1
(de)
|
2005-10-28 |
2014-05-07 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Expression des Huntingtin-Gens
|
CA2626584A1
(en)
|
2005-11-04 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of nav1.8 gene
|
CA2626690A1
(en)
|
2005-11-09 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor v leiden mutant gene
|
DE602007004463D1
(de)
|
2006-03-01 |
2010-03-11 |
Nippon Shinyaku Co Ltd |
Galactosederivat, arzneimittelträger und medizinische zusammensetzung
|
FR2898908A1
(fr)
|
2006-03-24 |
2007-09-28 |
Agronomique Inst Nat Rech |
Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
|
ES2544861T3
(es)
|
2006-03-31 |
2015-09-04 |
Alnylam Pharmaceuticals Inc. |
Composiciones y métodos para inhibir la expresión del gen Eg5
|
NZ572666A
(en)
|
2006-05-11 |
2010-11-26 |
Alnylam Pharmaceuticals Inc |
Compositions comprising double stranded rna and methods for inhibiting expression of the pcsk9 gene
|
WO2007137156A2
(en)
|
2006-05-19 |
2007-11-29 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of aha and therapeutic uses thereof
|
US7888498B2
(en)
|
2006-05-22 |
2011-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of IKK-B gene
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
KR20090083338A
(ko)
|
2006-09-18 |
2009-08-03 |
알닐람 파마슈티칼스 인코포레이티드 |
SCAP의 RNAi 조절 및 이들의 치료적 용도
|
AU2007299748A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
miR-15, miR-26, miR -31,miR -145, miR-147, miR-188, miR-215, miR-216 miR-331, mmu-miR-292-3p regulated genes and pathways as targets for therapeutic intervention
|
AU2007299804A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
MiR-200 regulated genes and pathways as targets for therapeutic intervention
|
WO2008036933A2
(en)
|
2006-09-21 |
2008-03-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the hamp gene
|
CN101627121A
(zh)
*
|
2006-12-08 |
2010-01-13 |
奥斯瑞根公司 |
作为治疗干预的靶标的miRNA调控基因和路径
|
CN101675165A
(zh)
*
|
2006-12-08 |
2010-03-17 |
奥斯瑞根公司 |
Let-7微小rna的功能和靶标
|
CA2671294A1
(en)
*
|
2006-12-08 |
2008-06-19 |
Asuragen, Inc. |
Mir-21 regulated genes and pathways as targets for therapeutic intervention
|
JP2010516786A
(ja)
|
2007-01-26 |
2010-05-20 |
ユニバーシティー オブ ルイヴィル リサーチ ファウンデーション,インコーポレーテッド |
ワクチンとしての使用のためのエキソソーム成分の改変
|
BRPI0809130A2
(pt)
|
2007-03-21 |
2014-08-26 |
Brookhaven Science Ass Llc |
Composições combinadas hairpin-antisenso e métodos para modulação da expressão
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
EP2905336A1
(de)
|
2007-03-29 |
2015-08-12 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Expression eines Gens von Ebola
|
US20090131354A1
(en)
*
|
2007-05-22 |
2009-05-21 |
Bader Andreas G |
miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
|
US20090232893A1
(en)
*
|
2007-05-22 |
2009-09-17 |
Bader Andreas G |
miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
|
US20090227533A1
(en)
*
|
2007-06-08 |
2009-09-10 |
Bader Andreas G |
miR-34 Regulated Genes and Pathways as Targets for Therapeutic Intervention
|
CN101688206B
(zh)
|
2007-07-05 |
2013-05-15 |
诺瓦提斯公司 |
用于治疗病毒感染的dsRNA
|
US8361714B2
(en)
*
|
2007-09-14 |
2013-01-29 |
Asuragen, Inc. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
WO2009108217A2
(en)
*
|
2007-09-18 |
2009-09-03 |
Intradigm Corporation |
Compositions comprising k-ras sirna and methods of use
|
WO2009039300A2
(en)
*
|
2007-09-18 |
2009-03-26 |
Intradigm Corporation |
Compositions comprising hif-1 alpha sirna and methods of use thereof
|
WO2009070805A2
(en)
*
|
2007-12-01 |
2009-06-04 |
Asuragen, Inc. |
Mir-124 regulated genes and pathways as targets for therapeutic intervention
|
EP2617828B1
(de)
|
2007-12-10 |
2014-09-24 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
|
WO2009086156A2
(en)
*
|
2007-12-21 |
2009-07-09 |
Asuragen, Inc. |
Mir-10 regulated genes and pathways as targets for therapeutic intervention
|
WO2009100430A2
(en)
*
|
2008-02-08 |
2009-08-13 |
Asuragen, Inc |
miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
|
AU2009221775B2
(en)
|
2008-03-05 |
2015-05-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
EP2268832A2
(de)
*
|
2008-03-06 |
2011-01-05 |
Asuragen, INC. |
Microrna-marker für das wiederauftreten eines kolorektalkarzinoms
|
US20110105588A1
(en)
*
|
2008-03-12 |
2011-05-05 |
Intradigm Corporation |
Compositions comprising notch1 sirna and methods of use thereof
|
EP2271757A2
(de)
*
|
2008-03-26 |
2011-01-12 |
Asuragen, INC. |
Zusammensetzungen und verfahren in zusammenhang mit mir-16 und prostatakrebstherapie
|
US20090258928A1
(en)
*
|
2008-04-08 |
2009-10-15 |
Asuragen, Inc. |
Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
|
US20110166198A1
(en)
*
|
2008-04-10 |
2011-07-07 |
Alnylam Pharmaceuticals, Inc. |
Rna compositions for modulating immune response
|
WO2009137807A2
(en)
|
2008-05-08 |
2009-11-12 |
Asuragen, Inc. |
Compositions and methods related to mirna modulation of neovascularization or angiogenesis
|
EP2293800B1
(de)
|
2008-06-06 |
2016-10-05 |
Quark Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von ohrerkrankungen
|
US9433684B2
(en)
|
2008-08-19 |
2016-09-06 |
Nektar Therapeutics |
Conjugates of small-interfering nucleic acids
|
EP3208337A1
(de)
|
2008-09-02 |
2017-08-23 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen zur kombinationshemmung der expression eines mutanten egfr und il-6
|
EP3584320A1
(de)
|
2008-09-25 |
2019-12-25 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der serum-amyloid-a-genexpression
|
CN106834291B
(zh)
|
2008-10-20 |
2020-09-29 |
阿尔尼拉姆医药品有限公司 |
抑制运甲状腺素蛋白表达的组合物和方法
|
WO2010056737A2
(en)
*
|
2008-11-11 |
2010-05-20 |
Mirna Therapeutics, Inc. |
Methods and compositions involving mirnas in cancer stem cells
|
WO2010065834A1
(en)
|
2008-12-04 |
2010-06-10 |
Opko Ophthalmics, Llc |
Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
|
AU2009324534B2
(en)
|
2008-12-10 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
GNAQ targeted dsRNA compositions and methods for inhibiting expression
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
WO2010105209A1
(en)
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
|
FR2944437B1
(fr)
*
|
2009-04-16 |
2013-05-10 |
Oreal |
Utilisation d'inhibiteurs de l'expression d'hif 1 alpha pour proteger la peau des dommages deleteres induits par le rayonnement uva
|
US9200276B2
(en)
|
2009-06-01 |
2015-12-01 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotides for multivalent RNA interference, compositions and methods of use thereof
|
NZ597504A
(en)
|
2009-06-15 |
2013-10-25 |
Alnylam Pharmaceuticals Inc |
Lipid formulated dsrna targeting the pcsk9 gene
|
US9051567B2
(en)
|
2009-06-15 |
2015-06-09 |
Tekmira Pharmaceuticals Corporation |
Methods for increasing efficacy of lipid formulated siRNA
|
WO2011020023A2
(en)
|
2009-08-14 |
2011-02-17 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
WO2011035065A1
(en)
|
2009-09-17 |
2011-03-24 |
Nektar Therapeutics |
Monoconjugated chitosans as delivery agents for small interfering nucleic acids
|
JP5574258B2
(ja)
*
|
2009-10-01 |
2014-08-20 |
学校法人東京女子医科大学 |
膵臓がん治療用の組成物
|
US8293718B2
(en)
|
2009-12-18 |
2012-10-23 |
Novartis Ag |
Organic compositions to treat HSF1-related diseases
|
KR20120125357A
(ko)
|
2010-02-10 |
2012-11-14 |
노파르티스 아게 |
근육 성장을 위한 방법 및 화합물
|
JP5860029B2
(ja)
|
2010-03-29 |
2016-02-16 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
トランスチレチン(TTR)関連眼アミロイドーシスのためのsiRNA療法
|
CA2801066C
(en)
|
2010-06-02 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
WO2012027206A1
(en)
|
2010-08-24 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
|
EP2433644A1
(de)
|
2010-09-22 |
2012-03-28 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Brustkrebstherapeutika
|
AR083445A1
(es)
|
2010-10-14 |
2013-02-27 |
Univ Mie |
siARN CONTRA LA FIBROSIS
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
WO2012064824A1
(en)
|
2010-11-09 |
2012-05-18 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
MX344807B
(es)
|
2011-06-21 |
2017-01-09 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibicion de genes para alipoproteina c-iii (apoc3).
|
EP2723865B1
(de)
|
2011-06-21 |
2019-03-27 |
Alnylam Pharmaceuticals, Inc. |
VERFAHREN ZUR BESTIMMUNG DER AKTIVITÄT VON RNAi IN EINEM PATIENTEN
|
WO2012177921A2
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc |
Compositions and methods for inhibiting hepcidin antimicrobial peptide (hamp) or hamp-related gene expression
|
WO2012178033A2
(en)
|
2011-06-23 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
US9644241B2
(en)
|
2011-09-13 |
2017-05-09 |
Interpace Diagnostics, Llc |
Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
|
AU2013208720A1
(en)
|
2012-01-09 |
2014-07-24 |
Arrowhead Research Corporation |
RNAi agents to treat Beta-Catenin related diseases
|
EP2700949A1
(de)
|
2012-08-24 |
2014-02-26 |
IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. |
Verwendung von Biliverdinreduktaseproteinen als Krebsmarker
|
JP6431035B2
(ja)
|
2013-03-13 |
2018-11-28 |
ジーンウィーブ バイオサイエンシズ,インコーポレイティド |
非複製的形質導入粒子及び形質導入粒子に基づくレポーターシステム
|
CA2909380A1
(en)
|
2013-04-21 |
2014-10-30 |
Yeda Research And Development Co. Ltd. |
Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w
|
BR112016019071A8
(pt)
|
2014-03-11 |
2021-07-06 |
Cellectis |
método para preparar uma célula t engenheirada, célula t engenheirada, e seus usos
|
WO2016077624A1
(en)
|
2014-11-12 |
2016-05-19 |
Nmc, Inc. |
Transgenic plants with engineered redox sensitive modulation of photosynthetic antenna complex pigments and methods for making the same
|
EP3261612A1
(de)
|
2015-02-26 |
2018-01-03 |
Yeda Research and Development Co. Ltd |
Verfahren zur förderung des haarwuchses
|
US20180036404A1
(en)
|
2015-03-02 |
2018-02-08 |
180 Therapeutics Lp |
Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
|
AU2016312530A1
(en)
|
2015-08-24 |
2018-03-01 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
KR20180054640A
(ko)
|
2015-08-25 |
2018-05-24 |
알닐람 파마슈티칼스 인코포레이티드 |
전구단백질 컨버타제 서브틸리신 켁신 (pcsk9) 유전자-관련 장애를 치료하기 위한 방법 및 조성물
|
EP3423568A4
(de)
|
2016-03-04 |
2019-11-13 |
University Of Louisville Research Foundation, Inc. |
Verfahren und zusammensetzungen zur ex-vivo-vermehrung von sehr kleinen embryonalen stammzellen (vsels)
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
MA45470A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques kras et leurs utilisations
|
MA45469A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques de bêta-caténine et leurs utilisations
|
MA45349A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques egfr et leurs utilisations
|
WO2018020012A1
(en)
|
2016-07-29 |
2018-02-01 |
Danmarks Tekniske Universitet |
Methods for decoupling cell growth from production of biochemicals and recombinant polypeptides
|
CA3066959A1
(en)
|
2017-06-16 |
2018-12-20 |
Imba - Institut Fur Molekulare Biotechnologie Gmbh |
Blood vessel organoid, methods of producing and using said organoids
|
SG11202005022YA
(en)
|
2017-12-06 |
2020-06-29 |
Avidity Biosciences Inc |
Compositions and methods of treating muscle atrophy and myotonic dystrophy
|
CN115666589A
(zh)
|
2020-03-19 |
2023-01-31 |
艾维迪提生物科学公司 |
治疗面肩肱型肌营养不良的组合物和方法
|